New approaches in the pharmacological treatment of obesity.
Many new substances are currently being investigated for their usefulness in the pharmaco-therapy of obesity. Most drugs interfere with monoamine neuro-transmitter (serotonin, noradrenalin, dopamine and histamine) effects and act as an appetite suppressant. Other approaches are to primarily increase thermogenesis (e.g. beta 3-adrenoceptor agonists), or to decrease fat absorption by inhibiting the pancreatic lipase (orlistat). New promising agents are substances that increase the effect of corticotropin releasing factor (CRF) or urocortin in the brain (CRF-binding protein ligand inhibitor) and a neuropeptide Y (NPY) Y5 receptor antagonist. The clinical relevance of leptin in the therapy of obesity is probably limited, but can not be fully evaluated at the moment. As obesity has a multifactorial basis, all these substances have in common the fact that they can not cure obesity. They should only be used as an adjunct to classical strategies like diet and exercise in severe obesity. For developing new, perhaps even more specific pharmacological agents, further research is needed to understand the individually different genetic and physiological basis of obesity.
Leonhardt
M
M
Institute of Animal Sciences, Swiss Federal Institute of Technology, ETH-Zentrum/LFW, Zürich, Switzerland.
Hrupka
B
B
Langhans
W
W
D000818:Animals; D001067:Appetite Depressants / Q000627:therapeutic use*; D001833:Body Temperature Regulation / Q000187:drug effects; D004041:Dietary Fats; D015195:Drug Design; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000502:physiology; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D018490:Serotonin Agents / Q000627:therapeutic use
D001067:Appetite Depressants; D004041:Dietary Fats; D018377:Neurotransmitter Agents; D018490:Serotonin Agents